516544AB9
Lantheus Holdings, Inc.
Could not find a ticker for this position, may be a filing error
A maker of radiopharmaceuticals used to image disease, Lantheus' products include PYLARIFY, an F-18 PET agent that lights up prostate cancer on scans, and DEFINITY, a contrast agent for heart ultrasound. The business began in 1956 as New England Nuclear, founded in Boston, and adopted the coined name "Lantheus" in 2008 when it became an independent company — a made-up brand invented to mark its fresh start.
CONVERTIBLEUnderlying: LNTHCUSIP: 516544AB9HealthcareUS1 derivative reporter
2.625% Convertible Senior Notes due 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
